AdaptHealth Reports Mixed Q1 Results, Raises Revenue Guidance, and Announces COO Transition
AHCO sits 56% above its 52-week low of $7.95.
Summary
AdaptHealth Corp. announced Q1 2026 results with increased revenue and raised full-year revenue guidance, but reported a wider net loss and negative free cash flow, alongside a COO termination and replacement.
Key Events · Earnings and Guidance · AHCO
-
Mixed Q1 2026 Financial Results
Net revenue increased 5.4% to $819.8 million, driven by 9.1% organic growth. However, net loss attributable to AdaptHealth Corp. widened to $16.0 million from $7.2 million year-over-year, Adjusted EBITDA decreased 5.3% to $121.2 million, and free cash flow worsened significantly to negative $27.5 million from negative $0.1 million.
-
Raised Full-Year Revenue Guidance
The company raised its fiscal year 2026 net revenue guidance by $10 million to a range of $3.45 billion to $3.52 billion, while maintaining Adjusted EBITDA and free cash flow guidance.
-
Chief Operating Officer Transition
Toby Scott Barnhart was terminated as Chief Operating Officer on May 4, 2026. Daniel McFadden, the current Chief Business Systems Officer, was immediately appointed as the new COO.
-
Strategic Refinancing and Asset Disposition
In April 2026, AdaptHealth completed a $1.1 billion refinancing of its senior secured credit facility, reducing near-term amortization and lowering the weighted average cost of debt. The company also disposed of its remaining custom rehabilitation assets to focus on core businesses.
Analysis · AHCO · Industrial Applications And Services
AdaptHealth Corp. reported a mixed first quarter, with strong organic revenue growth and a raised full-year revenue outlook, but also a widening net loss and significantly negative free cash flow. The company completed a major $1.1 billion refinancing of its senior secured credit facility, which is a positive for financial stability and debt management. However, the termination of the Chief Operating Officer, Toby Scott Barnhart, introduces an element of leadership uncertainty, despite the immediate internal appointment of Daniel McFadden. Investors should monitor the company's ability to improve profitability and cash flow generation in subsequent quarters, especially as it integrates its large de novo expansion and optimizes labor costs.
At the time of this filing, AHCO was trading at $12.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $7.95 to $13.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.